A Phase 2A Double-Blind Randomized, Controlled, Dose Escalation, Parallel- Arm, Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Acetazolamide (Primary) ; SASS 001 (Primary) ; Sivopixant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Shionogi-Apnimed Sleep Science
- 27 Jan 2025 Status changed from not yet recruiting to recruiting.
- 21 Jan 2025 New trial record